BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In one study, the knockdown of Fyn kinase via pharmacological inhibition or siRNA resensitized a BCR-ABL inhibitor imatinib-resistant chronic granulocytic leukaemia (CML) cell line (IM-R cells) to imatinib (Fenouille et al., 2010).